Melt Pharmaceuticals
Melt Pharmaceuticals is a clinical-stage pharmaceutical company developing non-opioid, non-IV sublingual sedation therapies for short-term medical procedures, with MELT-300 as its lead asset. Acquired by Harrow, Inc. in November 2025 to expand into needle-free procedural sedation.
- Company typePrivate
- Founded2019
- HeadquartersBrentwood, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Melt Pharmaceuticals does
Melt Pharmaceuticals is a privately held, clinical-stage pharmaceutical company founded in 2019 and based in Brentwood, Tennessee, focused on developing non-opioid, non-intravenous procedural sedation and analgesia therapies for short-term medical procedures. The company's core product, MELT-300, is a proprietary sublingual sedation formulation designed to deliver procedural sedation without opioid exposure or the logistical and infection risks associated with IV administration, targeting hospitals, ambulatory surgery centers, and clinics where opioid avoidance is a priority.
Melt operated with a lean team of 1–10 employees and raised approximately $47.8M cumulatively through SEC Form D exempt securities offerings (with $42.3M sold as of April 2024) to advance MELT-300 and other non-opioid sedation candidates toward FDA approval, targeted for 2028. Harrow, Inc. (NASDAQ:HROW) acquired Melt on November 18, 2025, through its subsidiary Harrow IP LLC, recording $8.5M in acquired in-process research and development expense and integrating MELT-300 into Harrow's portfolio to expand into the needle-free procedural sedation segment (a market projected at $29.91B by 2030 at a 9.7% CAGR).
Commercially, Melt was pre-revenue at acquisition: no products were approved or sold, no marketing or distribution infrastructure was disclosed, and revenue was expected to be generated through future pharmaceutical product sales contingent on regulatory clearance. As a wholly-owned subsidiary of Harrow, Melt's standalone commercial metrics are now subsumed into Harrow's broader ophthalmic-focused pharmaceutical operations.
Melt Pharmaceuticals firmographics
Firmographics- Name
- Melt Pharmaceuticals
- Legal name
- Melt Pharmaceuticals, Inc.
- Website
- https://meltpharma.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Melt Pharmaceuticals is a clinical-stage pharmaceutical company developing non-opioid, non-IV sublingual sedation therapies for short-term medical procedures, with MELT-300 as its lead asset. Acquired by Harrow, Inc. in November 2025 to expand into needle-free procedural sedation.
- Ownership category
- akta.pro rank
Melt Pharmaceuticals industry classification
Industry- Product category
- Procedural Sedation Pharmaceuticals
- NAICS
- Cookie, Cracker, and Pasta Manufacturing (31182), Cookie and Cracker Manufacturing (311821)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG)
- akta.pro secondary industry
- Hot/Cold Therapy Services (Cryotherapy/Ice Baths) (HSALAFAH)
Keywords
Where Melt Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Brentwood
- HQ country
- United States
- HQ region
- North America
Markets served
Melt Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical product sales: Melt Pharmaceuticals develops pharmaceutical products for procedural sedation. Revenue will be generated through product sales following regulatory approval. As of the November 2025 acquisition, products were in clinical development with planned regulatory submission by 2028.
Go-to-market motion1 record
Melt Pharmaceuticals product offering
Product offeringCore offering
Melt Pharmaceuticals develops non-opioid, non-IV sublingual sedation therapies intended for procedural sedation and analgesia during short-term medical procedures. Its lead candidate, MELT-300, is a proprietary sublingual formulation designed to deliver sedation without intravenous access or opioid exposure. Following the November 2025 acquisition by Harrow, Inc., Melt's products remain in clinical development with regulatory submission targeted for 2028.
Product overview
Melt Pharmaceuticals is a clinical-stage pharmaceutical company specializing in non-opioid, non-IV sedation therapies. The company's primary product is MELT-300, a sublingual sedation therapy designed to provide procedural sedation without the need for opioids or intravenous administration. The company was acquired by Harrow IP LLC in November 2025 to expand into needle-free procedural sedation. Clinical development and regulatory approval for MELT-300 are targeted for 2028.
Differentiator
Problem solved
Functional benefit
Brands
- MELT-300: Non-opioid, non-IV procedural sedation therapy product under development by Melt Pharmaceuticals, targeting transformation of procedural sedation and reduction of opioid exposure.
Products and services
- MELT-300 A non-opioid, non-IV sublingual procedural sedation therapy designed to transform procedural sedation and reduce opioid exposure in medical settings such as hospitals, ambulatory surgery centers, and clinics performing short-term procedures.
Companies that use Melt Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Melt Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Melt Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Harrow, Inc. (Harrow IP LLC)coreHarrow, Inc. acquired Melt Pharmaceuticals on November 18, 2025, through its subsidiary Harrow IP LLC. The acquisition was made to expand Harrow into needle-free procedural sedation. Melt's non-opioid, non-IV sedation therapies, including MELT-300, were integrated into Harrow's portfolio with plans for further clinical development and regulatory approval by 2028.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Melt Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- AcelRx Pharmaceuticals: Developer of sublingual sufentanil (DSUVIA) for procedural pain management in medically supervised settings. Highly comparable to Melt given its focus on sublingual drug delivery for acute procedural use cases in hospitals and surgical centers.
- Eagle Pharmaceuticals: Markets Byfavo (remimazolam), an injectable procedural sedation agent, along with other specialty injectable products. Directly comparable to Melt as a player in the procedural sedation pharmaceutical market with novel mechanism products.
- Acacia Pharma Group: Specialty pharmaceutical company focused on procedural sedation and supportive care, including licensing rights to Byfavo in the U.S. Directly comparable to Melt given its concentrated focus on the procedural sedation therapeutic area and hospital/ASC channel.
- Pacira BioSciences: Developer of EXPAREL, a long-acting non-opioid local anesthetic for postsurgical pain control. Comparable to Melt as a non-opioid specialty pharmaceutical company targeting the surgical and procedural care setting with differentiated delivery technology.
- Heron Therapeutics: Developer of ZYNRELEF, a non-opioid extended-release local anesthetic for postoperative pain, and other specialty pharmaceutical products. Comparable to Melt as a non-opioid procedural and postsurgical pain management company with hospital channel focus.
Emerging players
- Trevena Inc. Developed OLINVYK, an opioid-sparing IV analgesic for acute pain in hospital settings. Comparable as a smaller specialty pharma focused on opioid-alternative therapies for procedural and acute care use cases.
Broad incumbents
- Pfizer: Major pharmaceutical company that markets widely used procedural sedation agents including midazolam and other benzodiazepines. Comparable as the incumbent standard-of-care provider in procedural sedation against which Melt's novel non-opioid alternative will compete.
Others
- Harrow, Inc. Parent company of Melt following the November 2025 acquisition, and a publicly traded specialty ophthalmic pharmaceutical company. Included as the strategic acquirer and now operator of Melt's clinical pipeline, providing commercialization infrastructure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key highlights6 records
Customer concentration
Melt Pharmaceuticals social profiles
Digital presenceMelt Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Melt Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
Melt Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Melt Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Melt Pharmaceuticals
What does Melt Pharmaceuticals do?
Melt Pharmaceuticals develops non-opioid, non-IV sublingual sedation therapies intended for procedural sedation and analgesia during short-term medical procedures. Its lead candidate, MELT-300, is a proprietary sublingual formulation designed to deliver sedation without intravenous access or opioid exposure. Following the November 2025 acquisition by Harrow, Inc., Melt's products remain in clinical development with regulatory submission targeted for 2028.
Is Melt Pharmaceuticals a public or private company?
Melt Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.
When was Melt Pharmaceuticals founded?
Melt Pharmaceuticals was founded in 2019. It employs 1 to 10 people.
Where is Melt Pharmaceuticals based?
Melt Pharmaceuticals is headquartered in Brentwood, United States, in the North America region.
How does Melt Pharmaceuticals make money?
One revenue line is on record: pharmaceutical product sales.
Who are Melt Pharmaceuticals's main competitors?
Direct peers on record are AcelRx Pharmaceuticals, Eagle Pharmaceuticals, Acacia Pharma Group, Pacira BioSciences and Heron Therapeutics. Trevena Inc. is listed as an emerging player. Pfizer is listed as a broad incumbent. Harrow, Inc. is listed as an others.
Does Melt Pharmaceuticals have an API?
No public API is recorded for Melt Pharmaceuticals.
What industry is Melt Pharmaceuticals in?
Melt Pharmaceuticals's product category is Procedural Sedation Pharmaceuticals. Its primary akta.pro industry code is HLAIAGAG, Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors), with a secondary code of HSALAFAH, Hot/Cold Therapy Services (Cryotherapy/Ice Baths). Its NAICS code is 31182 and its SIC code is 2834.